Get the Daily Brief
Latest Biotech News
Regulatory and clinical trial signals in musculoskeletal and liver disease
A Phase 1 study evaluating the self-amplifying mRNA H5N1 vaccine ARCT-2304 found that spacing doses eight weeks apart produced stronger, longer-lasting antibody responses than a four-week...
RNAi IPOs and delivery strategies move into late-stage competition
City Therapeutics advanced its public-market visibility with a $200 million IPO aimed at pushing RNA interference therapies beyond the liver, a key hurdle for systemic delivery. The company’s...
AI and diagnostic workflows: precision pathology, imaging triage, and seizure risk
QuantumCyte’s digital pathology approach targets a long-standing limitation in solid-tumor sequencing—low tumor purity in biopsies that prevents reliable extraction of actionable DNA. The...
CAR-T and immune-oncology: early-stage durability signals and engineered next steps
A new phase 1 report on BCMA-targeted CAR-T therapy anito-cel in relapsed or refractory multiple myeloma reported responses in all 38 patients studied, paired with a favorable safety profile and...
Inflammation biology and targeted drug opportunities emerge from computational-to-bench links
Researchers reported a molecular convergence between gout-driven hyperinflammation and severe COVID-19 through matrix metalloproteinase MMP1. Using transcriptome dataset comparisons (GSE171110 for...
Sepsis and critical care diagnostics: turning biomarkers into certified decisions
A mini-review in Frontiers in Medical Technology argued that sepsis diagnosis remains bottlenecked not by a lack of biomarker candidates but by translation into certified in vitro tests that fit...
Rare disease gene therapies: non-dilutive funding via FDA rare pediatric PRVs
Ultragenyx agreed to sell a second rare pediatric Priority Review Voucher (PRV) for $203 million, following an earlier $210 million PRV sale linked to prior FDA approvals. The transaction brings...
Drug safety, stewardship, and antimicrobial resistance surveillance in hospitals
A Turkish study tracking antimicrobial resistance over 13 years in ICU patients with external ventricular drains found alarmingly high resistance in drain-associated brain infections, with...
Neurotherapeutics and device-based care: brain stimulation, BCI, and new measurement tools
A study combining high-frequency brain stimulation with recordings from living human cortical tissue reported selective activation of fast-spiking interneurons and lasting synaptic rebalancing,...
Metabolic and immune regulation: cross-disease targets and early pipeline cues
A commentary on efgartigimod in generalized myasthenia gravis highlighted a clinical gap: post-operative myasthenic crisis is often treated too late or as a diagnosis of exclusion. The authors...
European GLP-1 expansion
The European Medicines Agency’s human medicines committee (CHMP) endorsed Eli Lilly’s oral GLP-1 therapy orforglipron, clearing a regulatory milestone as the company tries to close the gap with...
AI-enabled target discovery dealmaking
AstraZeneca signed a $1.5 billion licensing and drug discovery collaboration with insitro to apply AI-driven target discovery to metabolic dysfunction–associated steatohepatitis (MASH) and...
RNAi public-market push
City Therapeutics priced a $200 million initial public offering to fund RNA interference programs aimed at moving beyond liver delivery. The company’s lead RNAi therapy portfolio and...
Therapeutic plasma exchange safety in pediatrics
A five-year retrospective single-center analysis of 144 critically ill children found therapeutic plasma exchange showed a generally strong safety profile. Researchers reported that multiple organ...
CAR-T clinical signal in myeloma
A phase 1 trial reported all 38 evaluable participants with relapsed or refractory multiple myeloma responded to the investigational BCMA-targeted CAR-T therapy anito-cel, with a favorable safety...
Rare pediatric PRV monetization by Ultragenyx
Ultragenyx agreed to sell a second rare pediatric disease priority review voucher for $203 million, bringing total voucher proceeds to $413 million within a week. The sale follows the FDA’s recent...
Clinical evidence for left atrial appendage occlusion
A sweeping review of randomized trial evidence found that left atrial appendage occlusion reduces non-procedural bleeding but did not lower mortality or all-cause major bleeding versus...
Immuno-oncology target biology in T-cell exhaustion
UCLA researchers identified the Cullin-5 RING E3 ligase complex as a driver of T-cell exhaustion using a genome-wide CRISPR screen. In preclinical models, blocking this pathway helped engineered...
Diagnostic AI for infant hip dysplasia
A machine learning model using 12 clinical and demographic variables flagged infants likely to need hip ultrasound before imaging, with strong external validation at a second hospital. The...
Regulatory scrutiny of peptide compounding and label updates
FDA and HHS submitted a peptide policy for White House review, outlining an interim access approach for compounding using certain peptides. Separately, the update package also covered label...